洞察市场格局
解锁药品研发情报

客服电话

400-9696-311
医药数据查询

首页 临床进展 Ovarian response in poor ovarian responder: a randomized controlled trial on the effect of mid-follicular phase recombinant luteinizing hormone versus low dose urinary human chorionic gonadotrophin supplement on in-vitro fertilization cycles

【ChiCTR-TRC-12002072】Ovarian response in poor ovarian responder: a randomized controlled trial on the effect of mid-follicular phase recombinant luteinizing hormone versus low dose urinary human chorionic gonadotrophin supplement on in-vitro fertilization cycles

查看原文
立即下载
基本信息
登记号

ChiCTR-TRC-12002072

试验状态

正在进行

药物名称

/

药物类型

/

规范名称

/

首次公示信息日的期

2012-04-04

临床申请受理号

/

靶点

/

适应症

women undergoing IVF-ET cycles

试验通俗题目

Ovarian response in poor ovarian responder: a randomized controlled trial on the effect of mid-follicular phase recombinant luteinizing hormone versus low dose urinary human chorionic gonadotrophin supplement on in-vitro fertilization cycles

试验专业题目

Ovarian response in poor ovarian responder: a randomized controlled trial on the effect of mid-follicular phase recombinant luteinizing hormone versus low dose urinary human chorionic gonadotrophin supplement on in-vitro fertilization cycles

申办单位信息
申请人联系人
请登录查看
申请人名称
请登录查看
联系人邮箱
请登录查看
联系人邮编

联系人通讯地址
请登录查看
临床试验信息
试验目的

The effect of mid-follicular phase recombinant luteinizing hormone versus low dose urinary human chorionic gonadotrophin supplement on in-vitro fertilization cycles

试验分类
请登录查看
试验类型

随机平行对照

试验分期

其它

随机化

RCT

盲法

Double-blind

试验项目经费来源

Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong

试验范围

/

目标入组人数

60

实际入组人数

/

第一例入组时间

1990-01-01

试验终止时间

1990-01-01

是否属于一致性

/

入选标准

1. History of 2 episodes of poor ovarian response (less than 3 mature follicles on ovulatory dose of hCG or less than 3 mature oocytes retrieved) despite maximal stimulation; or 2. Patients fulfill two out of three of the following features: I.Age >=40 or any other risk factors: (1)History of ovarian surgery; (2)History of salpingectomy; (3)History of chemotherapy; (4)Present of ovarian endometrioma.；

排除标准

1. Body mass index more than 30kg/m2; 2. Absent of one ovary; 3. History of polycystic ovarian disease; 4. Present of uterine abnormalities; 5. Present of endocrine/metabolic/autoimmune disease; 6. Incompetence or refuse for informed consent.；

研究者信息
研究负责人姓名
请登录查看
试验机构

Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong

研究负责人电话
请登录查看
研究负责人邮箱
请登录查看
研究负责人邮编

/

联系人通讯地址
请登录查看
更多信息
获取更多临床信息查看权限
立即前往摩熵医药企业版免费查询
示例数据
<END>

Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong的其他临床试验

更多

Prince of Wales Hospital的其他临床试验

更多

最新临床资讯

更多
摩熵医药企业版
50亿+条医药数据随时查
7天免费试用
体验产品